The purpose of the present invention is to provide an adhesion prevention material capable of exhibiting excellent adhesion preventive effect. This adhesion prevention material concurrently uses: (A) a peptide (A-1) having an amino acid sequence-(X-Pro-Y)n-[wherein X represents an arbitrary defined amino acid, Pro represents proline, Y represents hydroxyproline or proline, and n is an integer between 1 and 10] and/or a peptide (A-2) having an amino acid sequence-(Pro-Y)m-[wherein Pro represents proline, Y represents hydroxyproline or proline, and m is an integer between 1-10]; and (B) a gelatin gel. This adhesion prevention material exhibits a dramatically enhanced adhesion preventive effect as compared with the case where the abovementioned components are used individually, and in particular, has a markedly superior effect against adhesion of tendons.

A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.

A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.

In one aspect, the invention provides a composition comprising at least one monocyte comprising an agent that increases monocyte homing to a site of injury, and an effective amount of a drug. In another aspect, the invention provides a method of using the composition to deliver a drug to a site of injury.

In one aspect, the invention provides a composition comprising at least one monocyte comprising an agent that increases monocyte homing to a site of injury, and an effective amount of a drug. In another aspect, the invention provides a method of using the composition to deliver a drug to a site of injury.

Methods for treating psychiatric and psychological diseases or conditions, including depression, by use of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin are described. The methods can be used together with other agents for treatment of depression or other psychiatric or psychological diseases or conditions. Pharmaceutical compositions comprising at least one of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin together with a pharmaceutically acceptable excipient are also described. The pharmaceutical compositions can include other therapeutically active agents for the treatment of psychiatric or psychological diseases or conditions such as depression.

Methods for treating psychiatric and psychological diseases or conditions, including depression, by use of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin are described. The methods can be used together with other agents for treatment of depression or other psychiatric or psychological diseases or conditions. Pharmaceutical compositions comprising at least one of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin together with a pharmaceutically acceptable excipient are also described. The pharmaceutical compositions can include other therapeutically active agents for the treatment of psychiatric or psychological diseases or conditions such as depression.

It is provided new chemical entities allowing simultaneous diagnosis and treatment of cancers. More specifically, it is provided a theranostic compound consisting of a stabilized peptide ligand (agonists and antagonists) for the kinin B1 receptors (B1R) conjugated to specific radionuclides (e.g. .sup.64Cu) suitable for dual imaging/radiotherapy applications.

Methods for treating psychiatric and psychological diseases or conditions, including depression, by use of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin are described. The methods can be used together with other agents for treatment of depression or other psychiatric or psychological diseases or conditions. Pharmaceutical compositions comprising at least one of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin together with a pharmaceutically acceptable excipient are also described. The pharmaceutical compositions can include other therapeutically active agents for the treatment of psychiatric or psychological diseases or conditions such as depression.

Methods for treating psychiatric and psychological diseases or conditions, including depression, by use of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin are described. The methods can be used together with other agents for treatment of depression or other psychiatric or psychological diseases or conditions. Pharmaceutical compositions comprising at least one of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin together with a pharmaceutically acceptable excipient are also described. The pharmaceutical compositions can include other therapeutically active agents for the treatment of psychiatric or psychological diseases or conditions such as depression.